Structure Therapeutics
diabetes pill missed market expectations for weight loss in a
mid-stage trial and also fell short of results from a similar
treatment from rival Eli Lilly, sending the biotech.
Structure Therapeutic obesity pill shows promise in mid-stage trial marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
By Michael Erman (Reuters) -Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of re.
By Michael Erman (Reuters) -Structure Therapeutics diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results .